Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Roche, Zymeworks partner on lung cancer trispecific T cell engager ZW209, $55M upfront, $813M total
Licensing deal, oncology, antibody, milestone payments, royalties - Read more

Gilead Sciences acquires PepStar Therapeutics' IL-23R inhibitor program for $1.3B upfront
Licensing deal, autoimmune, small molecule, inflammatory bowel disease, milestone payments - Read more

Boehringer Ingelheim, Microsoft collaborate on AI-powered digital patient twins to transform clinical trials
Research collaboration, AI/ML, digital health, clinical trials, drug discovery - Read more

Marengo Therapeutics' (invikafusp alfa) shows tumor shrinkage across eight cancer types in Ph2
Antibody, cancer, bispecific antibody, solid tumors, T cell agonist, immune checkpoint - Read more

Alnylam plans pivotal trial for brezosiran (ALN-HTT02) targeting huntingtin protein in Huntington's disease after Ph1b success
RNAi therapy, neurological, Huntington's disease, huntingtin protein, siRNA, gene silencing - Read more

Boehringer Ingelheim shares Ph1b data on (obrixtamig) DLL3xCD3 bispecific for small cell lung cancer ahead of Ph3
Antibody, cancer, bispecific antibody, small cell lung cancer, DLL3, T-cell engager - Read more

Zentalis Pharmaceuticals' (azenosertib) shows 37.2% response rate in Ph1b platinum-resistant ovarian cancer trial
Small molecule, cancer, WEE1 inhibitor, ovarian cancer, Cyclin E1, cell cycle checkpoint - Read more

Takeda, Innovent Biologics' (arcotatug tavatecan) Ph3 trial shows survival benefit in claudin18.2-positive gastric and gastroesophageal junction adenocarcinoma
Antibody-drug conjugate, cancer, gastric cancer, CLDN18.2, ADC - Read more

Moderna, Merck & Co.'s (intismeran autogene)-Keytruda combo shows 42% risk reduction in Ph3 advanced melanoma trial
Vaccine, cancer, mRNA vaccine, melanoma, combination therapy, Keytruda - Read more

RiboX Therapeutics' (RXRG001) shows early Ph1/Ph2 promise for radiation-induced dry mouth targeting aquaporin-1
RNA therapy, head and neck cancer, circular RNA, aquaporin-1, xerostomia, lipid nanoparticle - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Argenx reports 54% growth in Q3 Vyvgart sales to $1.7B, with five potential launches planned for 2027 and 10 clinical molecules by year-end
FcRn blocker, autoimmune, financial, clinical trials, pipeline - Read more

Star Therapeutics raises $200M venture funding, advancing biologics for hematological and immune conditions
Rare disease, biologics, hematological, autoimmune, platform-enabled - Read more

Lycia Therapeutics raises $318M IPO, advancing protein-degrading LYTAC medicines pipeline
Protein degradation, autoimmune, allergy, small molecule, clinical-stage - Read more

Zai Lab plans $250M PIPE financing to advance DLL3-targeting ADC zocilurtatug pelitecan
Oncology, antibody-drug conjugate, clinical-stage, ADC - Read more

TriOar raises KRW 33B ($24.9M) Series C to advance ADC technology and drug pipeline
Antibody-drug conjugate, oncology, antibody therapeutics, preclinical, clinical-stage - Read more

Bolt Biotherapeutics acquires Prana Therapies in reverse merger with $120M financing for inflammation pipeline
Bispecific antibody, autoimmune, major transaction, strategic - Read more

FDA lifts clinical hold on Aardvark Therapeutics' ARD-101 after new cardiac safety data clears concerns
Small molecule, rare disease, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Gilead Sciences pays $45M to settle Texas AG's Medicaid kickback allegations over HIV drug prescriptions
Antiviral, infectious disease, financial, legal settlement - Read more

Apothecary Pharma recalls Eli Lilly’s Zepbound copycat, citing inability to guarantee medication safety
GLP-1 agonist, obesity, regulatory, competitive, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here